ArticleCardiovascular diabetology2025
Cardiometabolic risk factors and disease trends for atrial fibrillation in individuals with type 1 diabetes: a nationwide registry study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-alcoholic fatty liver disease as a predictor of atrial fibrillation recurrence following ablation: a retrospective study.Cardiovascular diagnosis and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate standardized incidence of atrial fibrillation (AF) in individuals with type 1 diabetes (T1DMM) compared with matched controls from the general population. Additionally, to examine optimal levels- and relative importance of risk factors associated with AF and numbers of risk factors necessary to reduce excess risk in individuals with T1DM. RESEARCH DESIGN AND
methodsThe study included individuals with T1DM between 2001 and 2019 and matched controls without T1DM. The outcome of interest was the first occurrence of AF. Standardized incidence rates and Cox regression were used for analyzing incidence and risk associations.
resultsThe study comprises analyses of data from 36,069 persons with T1DM and 165,705 matched controls; average age 34.1; 43.2% women. Incidence rates per 100,000 person years for AF in persons with T1DM declined between 2001 and 2019 from 671 to 494; also in controls from 568 to 317. However, results shows that those without cardiovascular disease at baseline, did not display a similar rate reduction over time. During this period, people with T1DM had a 1.34-fold (95% CI 1.24-1.46) higher adjusted hazard for incident AF than controls when adjusting for sociodemographic factors. This hazard was attenuated to 0.95 (95% CI 0.87-1.03) after also accounting for coronary, cerebrovascular, kidney disease and heart failure; among those with T1DM. In those, with several risk factors at baseline, we observed a hazard ratio from 1.61 (95%, 1.07-2.43), and there was also an indication of clear risk reduction in those with zero risk factors, albeit non-significant (HR 0.60, 95% CI 0.35-1.04). In the T1DM cohort, the first available value of hemoglobin A1c, systolic blood pressure, body mass index and estimated glomerular filtration rate were each independently associated with incident AF and we noticed a clear linear risk increase for several cardiometabolic risk factors.
conclusionsThe crude incidence of AF was higher for persons with versus without T1DM, and declined significantly in both groups. Adjusting for data-derived predictors of AF attenuated higher risks, suggesting that the higher AF risk for persons with T1DM is driven by its common comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.